Product brand of Guangdong Guoyitang Pharmaceutical Co., Ltd.

Traditional Chinese medicine hall culture

Chinese herbal medicines are the basis for preparing Chinese herbal pieces; Chinese herbal pieces are an important link in the production of Chinese herbal preparations; The stability of the quality of traditional Chinese medicine depends on the quality of decoction pieces. Guoyitang Pharmaceutical Co., Ltd. has produced a large number of Chinese patent medicines for a long time, and deeply felt the influence of uneven quality of medicinal materials on the quality of Chinese medicine.

For a long time, there is no unified standard for the production of Chinese herbal medicines and Chinese herbal pieces in China. Therefore, the US Food and Drug Administration requires GMP transformation and certification of the production of Chinese herbal pieces, which will ensure the quality of Chinese medicine.

The Guangdong production base of Guoyitang Pharmaceutical has excellent climate, geography and environment, which is very suitable for the production of local medicinal materials. After many investigations and demonstrations by experts of traditional Chinese medicine, it is suggested that we should give full play to local advantages, make use of valuable geothermal resources, carry out planting, breeding and processing of Chinese herbal medicines, and establish a unique drug source base. With the support of the local government, the first batch of 200 mu provenance bases have been approved for purchase and use by the government. Therefore, the establishment of Guangdong Guoyitang Yao Yuan Base Co., Ltd. with the National Chinese Herbal Medicine Group * * and the joint promotion of the industrialized operation of Chinese herbal medicines with the local drug administration and agricultural management departments will help to explore and formulate unified standards for the production of Chinese herbal medicines and Chinese herbal pieces, ensure the quality of Chinese herbal medicines and increase the income of local farmers.

In 2003, Guoyitang Pharmaceutical Co., Ltd. obtained the qualification of the first batch of Chinese herbal pieces production and labeling by the State Food and Drug Administration of the United States. The close combination of drug source base and traditional Chinese medicine decoction pieces has formed the industrial chain of traditional Chinese medicine pharmacy, achieving a win-win situation for social benefits and enterprise development.

The research and introduction of drugs is the lifeline of pharmaceutical enterprises.

Guoyitang Holdings sincerely invites the backbone R&D team with top academic level, leading technology, strong sense of responsibility and sincere unity. They have been engaged in drug research for a long time with a wide range of research topics. They have a certain understanding of new drugs, special drugs and generic drugs, rich technical experience and profound professional knowledge. They are experts and scholars who are familiar with the development trend of the pharmaceutical industry at home and abroad. Among them, there are full-time R&D personnel 19 (5 in Gao Zheng, 6 in technical secondary school and 8 in intermediate level) and part-time medical experts 15 (8 in Gao Zheng and technical secondary school). Therefore, Beijing Institute of Traditional Chinese Medicine was established with capital injection, which cooperated with professional colleges and scientific research institutions in China and Beijing and Guangzhou, established close cooperative relations and formed information sources. It enabled Guoyitang Pharmaceutical to complete the practical work of extraction, separation, purification, preparation, analysis, registration, drug effectiveness and safety evaluation, pilot scale-up, etc., reserve a large number of new products of commonly used drugs and special drugs, obtain 5 exclusive patented technologies, and successfully register 99 trademarks of traditional Chinese medicines and health care products, laying a technical foundation for realizing the scientific and technological development and sustainable development of enterprises.

Guoyitang Pharmaceutical Co., Ltd. integrates the information flow, logistics and capital flow of drugs and health care products into a whole by using PM system, and builds a regional marketing network covering Beijing, Shanghai, Guangdong, Chongqing, Sichuan, Guangxi, Yunnan, Zhejiang, Jiangsu, Anhui, Hebei, Henan, Shandong, Shanxi, Shaanxi, Liaoning, Jilin, Heilongjiang and Canada, realizing the goal of fixing production by sales and stabilizing sales by production.

In terms of capital market, after the continuous development of Sinopharm Center and the continuous leap-forward development of production, R&D, sales and services, in order to consolidate the operating results of the enterprise and seize the development opportunity, it was decided by the shareholders' meeting to strengthen and expand Sinopharm Center, upgrade and upgrade its scale, and realize the medium-term goal of building a backbone enterprise of pharmaceutical production. According to the relevant provisions of the Company Law and the Securities Law, in April 2004, three prestigious professional securities, legal and auditing institutions were entrusted as intermediaries to fully implement the restructuring and construction of the modern enterprise system in three stages: restructuring, issuance counseling and stock listing, in terms of capital verification audit, legal certification, market access counseling and sponsorship underwriting. After a year and a half of systematic work, on June 5438+ 10, 2005, the Guangdong provincial government approved the overall change of Guangdong Guoyitang Pharmaceutical Co., Ltd. to be established as Guangdong Guoyitang Pharmaceutical Co., Ltd., and completed the registration procedures of the joint-stock company in the Provincial Administration for Industry and Commerce. At this point, the enterprise restructuring procedure of Guoyitang Pharmaceutical has been completed, and it entered the pre-issuance counseling in 2006. The company strives to publicly issue Guoyitang Pharmaceutical shares as soon as possible, enter the national capital market, and complete the transformation and construction of the modern enterprise system. When stocks are listed and issued and integrated into the capital market, it is the day of strategic development.